Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
<p>Background: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) ch...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Massachusetts Medical Society
2014
|